Compare Definium Therapeutics Inc. Common Shares (DFTX) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs DexCom, Inc. — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while DexCom, Inc. trades at $84.38 (market cap $31.81B). The key difference: DexCom, Inc. is far larger — about 6.8× Definium Therapeutics Inc. Common Shares's market cap, and DexCom, Inc. is trading nearer its 52-week high, Definium Therapeutics Inc. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and DexCom, Inc. for 62 Days on average.
| DFTX | DXCM | |
|---|---|---|
Market Cap | $4.71B | $31.81B |
Volume | 1,966,636 | 2,861,821 |
Sector | Health | Health |
52-Week High | $48.45 | $92.34 |
52-Week Low | $10.68 | $54.84 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $3.67B | $31.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
